Tutorials › CAS Exam 9 - Risk Management for Actuaries › Board Oversight of ORSA

CAS Exam 9 · ORSA Purpose and Governance · Tutorial 807 of 995

Board Oversight of ORSA

Learn what effective board oversight of ORSA requires, what information supports it, and how the assessment should inform risk and capital decisions.

Intermediate 11 min read

What You'll Learn

  • Identify the board’s core ORSA oversight responsibilities and boundaries.
  • Set expectations for the assessment’s purpose, scope, and connection to strategy.
  • Evaluate whether ORSA information is timely, decision-useful, and clear about uncertainty.
  • Connect stress results and capital projections to governance decisions.
  • Recognize common weaknesses in board reporting and follow-up.

Why Board Oversight Matters

An Own Risk and Solvency Assessment (ORSA) is an insurer-owned assessment of its risk profile and solvency needs. Its value depends not only on the analyses prepared, but also on whether the insurer’s governing board establishes appropriate expectations and uses the assessment in its oversight. A report can be extensive and technically sophisticated yet have little governance value if it does not help the board understand the insurer’s risks, capital position, and choices.

The board’s role is to oversee the framework and its use, not to perform the underlying actuarial or risk analysis. Effective oversight makes clear what the assessment is expected to cover, ensures that the board receives information suited to its responsibilities, and connects the assessment to the insurer’s risk and capital governance. These responsibilities support an ORSA that reflects the insurer’s own view of risk rather than a document prepared only to meet a reporting deadline.

Definition: Board oversight of ORSA is the board’s governance of the assessment’s purpose, expectations, information flows, and use in decisions about risk and capital. It includes monitoring whether the assessment remains relevant to the insurer’s risk profile and strategy; it does not mean that directors calculate the results or manage individual risks.

This tutorial is aligned with the CAS Exam 9 (Risk Management for Actuaries) syllabus. Its focus is the board’s ongoing oversight responsibilities. The board’s oversight should be informed and active, while technical preparation remains with the appropriate management and specialist processes.

Setting Expectations for the Assessment

The board should establish the outcomes it expects ORSA to support. Those expectations give management and the people preparing the assessment a clear governance purpose. They also help the board distinguish a useful assessment from a compilation of risk descriptions and model outputs.

At a minimum, board-level expectations should make clear that the assessment is intended to:

  • Reflect the insurer’s own material risks, business profile, and relevant group or entity boundaries.
  • Consider how strategy and planned business changes affect risk and solvency over an appropriate planning horizon.
  • Provide a reasoned view of capital needs, including how that view may change under adverse conditions.
  • Support decisions about risk-taking, capital management, and responses to material changes.
  • Communicate important assumptions, limitations, uncertainty, and areas where management judgment affects the conclusions.

The board need not prescribe every model, data source, or calculation. Those choices require technical expertise and may change as the insurer’s methods develop. Instead, the board sets the governance expectation: the methods used should be appropriate to the risks, and the resulting information should be sufficiently clear to support oversight. For instance, asking that an assessment consider a sustained adverse scenario is a governance expectation; selecting the detailed parameterization of that scenario is a technical task.

Expectations should also be proportionate. An assessment should not become needlessly elaborate in areas that have little bearing on the insurer’s risk profile, while material risks should not be omitted merely because they are difficult to quantify. The board can expect material qualitative risks to be described and governed even when a precise capital estimate is not available.

Receiving Information That Supports Oversight

A board needs more than a headline solvency figure. It needs information that explains what the figure represents, how it relates to the insurer’s risk profile, and what could cause the conclusion to change. This does not mean that every technical detail belongs in the board materials. The aim is to provide a clear route from risk, through assessment, to governance implications.

Key takeaway: Board information is decision-useful when directors can identify the material risks assessed, the time horizon and assumptions behind important results, the effect of adverse conditions, the main limitations, and the decisions or monitoring actions that follow.

A useful board package commonly distinguishes the current position from projected positions, and the central view from adverse scenarios. It should explain whether capital resources remain adequate in those views and identify important sensitivities. Where a result depends materially on an assumption, the board should be able to see that dependence rather than encounter a single number without context.

Information also needs to be timely and appropriately escalated. A significant change in the insurer’s risk profile can make a previously prepared assessment less informative. Board oversight should therefore include expectations for how material developments are brought into governance, rather than relying only on a periodic report. The precise reporting arrangements may vary with the insurer, but the board should understand how it will be kept informed when circumstances change.

In reviewing the information provided, directors should be able to distinguish:

  • Risk information: what exposures and material changes are relevant to the insurer.
  • Assessment information: how those exposures affect the insurer’s view of solvency across the stated horizon and scenarios.
  • Governance information: what the results imply for risk limits, capital plans, monitoring, or other decisions.

If one of these links is missing, the board may see a technically correct result without understanding its significance. A solvency projection, for example, does not by itself explain whether a proposed business plan remains consistent with the board’s risk expectations.

Connecting ORSA to Risk and Capital Governance

ORSA should inform governance rather than sit alongside it as an isolated exercise. The board can use the assessment to understand whether the insurer’s strategy is consistent with its risk appetite, whether capital plans remain credible under adverse conditions, and whether risk-taking requires additional monitoring or a management response. These are governance uses of the assessment; ORSA does not replace the board’s other oversight processes.

A practical connection begins with a traceable chain: a strategic or risk change affects exposures; those exposures affect the assessment; the assessment produces conclusions about solvency or uncertainty; and those conclusions are considered in the relevant governance decision. If the insurer changes its business plan, for example, the board should be able to understand whether the changed plan has been reflected in the assessment or what interim safeguards apply while it is evaluated.

1
Set the governance question.
Identify what the board needs ORSA to help oversee, such as whether a planned strategy remains consistent with the insurer’s risk and capital expectations.
2
Receive relevant evidence.
Review the risk profile, projections, adverse scenarios, assumptions, and limitations that bear on that question.
3
Connect conclusions to governance.
Consider whether the evidence affects risk monitoring, capital planning, or the conditions under which a proposed course of action is acceptable.
4
Monitor changes and follow-up.
Expect material developments and agreed responses to return through appropriate governance information flows.

This chain gives ORSA a continuing role. It does not require the board to manage each exposure directly. The board’s responsibility is to ensure that material implications reach the appropriate governance forum and are not lost between technical analysis and business decisions.

Worked Example: Setting Expectations for a Capital Plan

A hypothetical insurer reports capital of $620 million at the start of its planning period. Under its proposed plan, projected capital before a stress is $590 million. A specified adverse scenario reduces that projection by $110 million. The board has set an internal capital floor of $450 million. Management is also considering a $50 million distribution. What should the board learn from the ORSA information, and what is the relevant comparison?

Method. Compare the stressed projection with the board’s stated floor, then calculate the effect of the proposed distribution. Treat the figures as a simplified governance illustration, not as a regulatory capital formula.

Step 1: Calculate capital under the adverse scenario before the distribution. The stressed projection is $590 million minus $110 million, or $480 million.

Step 2: Compare it with the internal floor. The margin is $480 million minus $450 million, or $30 million. On these stated assumptions, the stressed projection is $30 million above the floor before the proposed distribution.

Step 3: Include the proposed distribution. After a $50 million distribution, the stressed projection would be $480 million minus $50 million, or $430 million.

Step 4: Compare the resulting amount with the floor. The shortfall is $450 million minus $430 million, or $20 million. The distribution changes the illustrated conclusion from $30 million above the floor to $20 million below it.

The board’s oversight question is whether the assessment and capital-governance process adequately reflect this consequence before the plan proceeds. It should receive the assumptions and limitations behind the projection and understand whether any proposed response changes the conclusion.

Check. $430 million is $20 million below the stated $450 million floor, so the arithmetic is consistent. A common mistake is to compare the floor with the pre-distribution stressed amount of $480 million and overlook the proposed action. The correction is to include the action in the scenario being considered.

Worked Example: Assessing Whether a Board Report Is Decision-Useful

A hypothetical insurer’s board receives a report stating that projected capital is $310 million, with a “downside result” of $265 million. The report does not state the projection horizon, explain the downside scenario, show the internal capital threshold of $280 million, or identify whether a planned product expansion is included. Determine what information is missing and what conclusion the board can responsibly draw.

Method. Test whether the figures are interpretable, comparable with the insurer’s governance threshold, and relevant to the plan under consideration.

Step 1: Establish what the figures represent. The report gives two capital amounts, but without a horizon the board cannot tell when they apply. Without a scenario description, it cannot tell what adverse conditions the downside result represents.

Step 2: Compare the downside with the stated threshold. If the $265 million result is on a basis comparable with the $280 million threshold, it is $280 million minus $265 million, or $15 million below that threshold. The report does not establish whether the bases are comparable, so the board cannot treat this as a confirmed threshold breach.

Step 3: Test relevance to the proposed expansion. Because the report does not say whether the expansion is included, the results cannot yet be used to judge the expansion’s effect on the capital outlook.

Conclusion. The board can identify a potentially important signal, but it cannot draw a reliable conclusion about the expansion or the threshold comparison without the missing context. It should expect the information needed to interpret the projection and relate it to the proposed plan.

Check. The arithmetic difference is $15 million, but that difference alone does not prove a comparable shortfall. A common mistake is to treat every reported number as directly comparable. The correction is to establish the horizon, scenario, and measurement basis before interpreting the difference.

Worked Example: Connecting a New Business Plan to ORSA

A hypothetical insurer has $260 million of projected capital before a planned product launch. Its internal capital threshold is $220 million. Management estimates that the launch would use $25 million of capital in the central projection. Under a relevant adverse scenario, the launch is estimated to reduce capital by $30 million instead. Assuming these amounts are measured on a consistent basis, what do the two projections show, and what is the board-level implication?

Method. Calculate capital after the launch in the central projection and in the adverse scenario, then compare both amounts with the threshold.

Step 1: Calculate the central projection after the launch. $260 million minus $25 million equals $235 million.

Step 2: Calculate the adverse projection after the launch. $260 million minus $30 million equals $230 million. This is the adverse result using the figures provided; it is not a separate additional $30 million reduction after the central $25 million reduction.

Step 3: Compare each result with the threshold. The central margin is $235 million minus $220 million, or $15 million. The adverse margin is $230 million minus $220 million, or $10 million.

Conclusion. Both stated projections are above the threshold, but the adverse margin is smaller. The board should ensure the assessment’s assumptions, uncertainty, and relevance to the launch are visible in the decision process and that the capital position will be monitored as the plan develops.

Check. The adverse result is $230 million, not $205 million. A common mistake is to subtract both the $25 million central use and the $30 million adverse reduction from the same starting amount, even though the problem defines them as alternative projected reductions. The correct comparisons are $260 million minus $25 million and $260 million minus $30 million.

Common Oversight Pitfalls

PitfallWhy it weakens oversightBetter practice
Focusing only on a headline capital figureThe figure may hide the horizon, scenario, assumptions, and sensitivity that determine its meaning.Expect a concise explanation of the basis, key drivers, and governance implications.
Treating ORSA as a periodic report aloneMaterial changes between reporting dates may make the assessment less relevant to current decisions.Expect suitable escalation and consideration of material changes in the risk profile.
Assuming technical detail equals decision usefulnessComplex output may not explain what the board needs to oversee.Require a clear connection between risk, assessment results, and capital or risk governance.
Taking over technical preparationBoard involvement in detailed calculations can blur the distinction between oversight and execution.Set expectations for appropriate analysis and receive explanations that support informed oversight.
Ignoring uncertainty or limitationsA precise-looking result may be mistaken for certainty.Expect important assumptions, limitations, and sources of uncertainty to be communicated.

The central governance test is not whether the board has seen every model output. It is whether the board can understand the material conclusions, recognize where those conclusions are uncertain, and see how the assessment informs decisions and monitoring. That is what makes ORSA an active part of risk and capital governance rather than a standalone compliance exercise.

Check Your Understanding

Work through each problem, then compare your result with the answer provided.

  1. A hypothetical insurer’s capital is projected at $410 million under its central plan and $365 million under an adverse scenario. Its board-set internal floor is $380 million. Calculate the adverse shortfall and state one piece of context the board should receive before interpreting it. (Answer: $15 million below the floor; the board should know the scenario and measurement horizon, among other relevant context.)
  2. A report gives a projected capital amount of $225 million but does not say whether a planned acquisition is included. What is the governance limitation, and what should the board expect before using the result to oversee the acquisition? (Answer: The acquisition’s effect is unknown; the board should receive a projection that clearly states whether and how the acquisition is reflected, with relevant assumptions and scenario context.)
  3. A hypothetical insurer starts with projected capital of $500 million. A planned action reduces it by $35 million in the central projection and by $60 million in an adverse projection. The internal floor is $450 million. Calculate both margins above or below the floor and identify which is tighter. (Answer: Central projection $465 million, or $15 million above the floor; adverse projection $440 million, or $10 million below it. The adverse margin is tighter.)
  4. A board receives a downside capital result of $292 million against a $300 million internal threshold. The report does not explain whether the result includes a proposed $18 million distribution. If it does not include the distribution, calculate the adjusted result and shortfall, then state the reporting issue. (Answer: Adjusted result $274 million; shortfall $26 million. The board needs a result that explicitly includes the proposed distribution, along with the basis and scenario information needed to interpret it.)
  5. A business plan produces $540 million of projected capital before a new initiative. The initiative reduces central projected capital by $20 million and adverse projected capital by $55 million. The internal floor is $500 million. Calculate each projection and margin, then state the key oversight implication. (Answer: Central projection $520 million, $20 million above the floor; adverse projection $485 million, $15 million below it. The board should receive the adverse implication and relevant assumptions in the governance process before relying on the central result alone.)
Clinical Biostats